AstraZeneca plc (NYSE:AZN) has received an average recommendation of “Hold” from the thirty research firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $34.54.
Several equities research analysts recently weighed in on AZN shares. Citigroup Inc. raised AstraZeneca plc to a “buy” rating in a report on Wednesday, October 18th. Cowen and Company restated a “hold” rating and issued a $37.00 target price on shares of AstraZeneca plc in a research note on Tuesday, October 17th. Leerink Swann raised their target price on AstraZeneca plc from $31.00 to $34.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Credit Suisse Group upgraded AstraZeneca plc from a “neutral” rating to an “outperform” rating in a research report on Monday, October 16th. Finally, BMO Capital Markets set a $38.00 price target on AstraZeneca plc and gave the company a “buy” rating in a research report on Tuesday, October 31st.
Several large investors have recently made changes to their positions in the company. Wrapmanager Inc. lifted its holdings in shares of AstraZeneca plc by 21.1% during the third quarter. Wrapmanager Inc. now owns 52,340 shares of the company’s stock valued at $1,773,000 after purchasing an additional 9,120 shares in the last quarter. FDx Advisors Inc. lifted its holdings in shares of AstraZeneca plc by 21.9% during the third quarter. FDx Advisors Inc. now owns 143,702 shares of the company’s stock valued at $4,869,000 after purchasing an additional 25,838 shares in the last quarter. Bessemer Group Inc. increased its position in AstraZeneca plc by 195.7% during the third quarter. Bessemer Group Inc. now owns 7,084 shares of the company’s stock valued at $240,000 after acquiring an additional 4,688 shares during the last quarter. Becker Capital Management Inc. increased its position in AstraZeneca plc by 7.2% during the third quarter. Becker Capital Management Inc. now owns 1,499,012 shares of the company’s stock valued at $50,787,000 after acquiring an additional 100,835 shares during the last quarter. Finally, Gabelli Funds LLC increased its position in AstraZeneca plc by 7.9% during the third quarter. Gabelli Funds LLC now owns 196,000 shares of the company’s stock valued at $6,640,000 after acquiring an additional 14,400 shares during the last quarter. 14.18% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca plc (AZN) traded up $0.37 during trading on Friday, hitting $34.48. The company’s stock had a trading volume of 2,924,097 shares, compared to its average volume of 3,505,970. The stock has a market capitalization of $87,297.36, a P/E ratio of 7.85, a PEG ratio of 2.76 and a beta of 0.75. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.73 and a current ratio of 0.91.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about AstraZeneca plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca plc and related companies.